Lithium and GLP-1-based therapies in bipolar disorder: an emerging pharmacovigilance signal and monitoring considerations

International Clinical Psychopharmacology · Published 2026-07-28 · DOI 10.1097/yic.0000000000000636

Authors (3)

Ervin Cotrik, Antônio Geraldo da Silva, Jair C. Soares

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Cotrik, E., Silva, A., Soares, J. (2026). Lithium and GLP-1-based therapies in bipolar disorder: an emerging pharmacovigilance signal and monitoring considerations. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000636

Related articles

• Question · Journal of Clinical Psychopharmacology · 2026 · Cites or is cited by this article
• Potential protective role of GLP-1 receptor agonists for lithium-induced nephrotoxicity: a population-based observational study · CNS Spectrums · 2025 · Cites or is cited by this article
• A Case of GLP-1 Receptor Agonist-Induced Lithium Neurotoxicity · Journal of Psychiatric Practice · 2026 · Cites or is cited by this article
• Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management · Mental Health Clinician · 2026 · Cites or is cited by this article
• Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial · International Clinical Psychopharmacology · 2025 · Same journal
• Unspoken needs: an essential perspective in the treatment of schizophrenia · International Clinical Psychopharmacology · 2026 · Same journal
• When antidepressants meet the gut microbiota: implications and challenges · International Clinical Psychopharmacology · 2024 · Same journal
• Innovations and challenges in antipsychotic treatments and external modulating factors · International Clinical Psychopharmacology · 2025 · Same journal
• Brexpiprazole augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary retrospective observational study · International Clinical Psychopharmacology · 2025 · Same journal
• The effects of lurasidone on five symptom domains and individual items in schizophrenia: Post-hoc analysis from Phase 3 study · International Clinical Psychopharmacology · 2025 · Same journal